Management of Obesity: The Surgical Perspective by Dodiyi-Manuel, A & Dodiyi-Manuel, S
Page 01
Type of Article: Review
The Nigerian Health Journal, Vol. 12, No 1, January - March,  2012
INTRODUCTION
Obesity is a state of  excess adipose tissue mass resulting in 
2 Body Mass Index (BMI) of  30kg/m or greater. 
BMI is calculated by dividing the weight (in kilograms) by the 
2square of  height (in meters). BMI between 25 and 29.9kg/m  
2is termed overweight. Morbid obesity is BMI of  40kg/m  or 
1greater . 
There are other indices used to identify obesity such as the 
waist-hip ratio which is the ratio of  waist circumference 
(measured at midpoint between the lower margin of  the last 
palpable rib and the top of  ileal crest) to hip circumference 
(measured around the widest portion of  the buttocks). 
The ideal body weight which is 50kg + 2.3kg for every inch 
over 5ft for men and 45.5kg + 2.3kg for every inch over 5 ft for 
women can also be used as an index of  obesity. 
Obesity is at present a major health problem and one of  the 
most prevalent diseases globally which imposes devastating 
health and financial burden on the victims and society. 
Despite the increasing awareness of  this burden, obesity with 
2its co-morbidities continues to increase at an alarming rate .
Many reports have emphasized the alarming increase in the 
prevalence of  obesity and overweight in the United States of  
3-5America . A study estimates the combined prevalence of  
obesity and overweight to be over 64% of  the United States 
5(US) adult population with 4.7% as morbid obesity . In the 
US, obesity and its complications result in about 300,000 
6deaths annually . 
As a result of  the increase in incidence, treatment options for 
obesity have become more numerous including non medical 
options, with increasing rates of  bariatric surgery as shown in 
California where the number of  bariatric surgeries rose from 
71134 in 1996 to 6304 in 2000 .
The prevalence rates of  obesity and its co morbidities like 
hypertension, diabetes and dyslipidaemia in developing 
countries are relatively low but are changing rapidly with 
8  urban and rural variations .  In Nigeria, the prevalence rate 
9reported from a study in Okrika in Rivers State was 16.3% . 
Paradoxically, the access to bariatric surgeries in developing 
countries like Nigeria is limited and rare.
The objective of  this review is to give an overview of  bariatric 
surgical procedures, evaluate the possible outcomes, 
recommend preferred methods and create awareness among 
surgeons on the expected increase in demand for bariatric 
surgeries by patient s in Nigeria.
     
Obesity: Pathogenesis and complications
Obesity is the result of  multifactorial changes involving both 
environment and genetic factors.  Accumulation of  fat results 
when energy consumption exceeds energy expenditure over a 
long period of  time and the discrepancy becomes too large to 
be detected by the hypothalamic regulation of  the Basal 
10Metabolic Rate .
Ghrelin is the first circulating hunger hormone. It is a 
hormone produced mainly by the P/D1 cells lining the 
fundus of  the stomach and epsilon cells of  the pancreas that 
11stimulate hunger . The levels which increase before meals 
and decrease after meals are lower in the plasma of  obese than 
leaner individuals. In some bariatric procedures, the level of  
ghrelin is reduced in patients causing satiation before it would 
12normally occur. Ghrelin increases food intake and fat mass  
by an action exerted on the hypothalamus. It activates cells in 
13the arcuate nucleus  that include the orexigenic neuropeptide 
14Y(NPY) neurons . Ghrelin responsiveness of  these neurons 
is both leptin and insulin sensitive. It also activates the 
mesolimbic cholinergic-dopaminergic reward link, a circuit 
that communicates the hedonic and reinforcing aspects of  
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15 natural rewards, such as food leading to increase fat mass.
Genetic factors have led to the discovery of  ob gene which is 
expressed solely in both white and brown adipose tissue. The 
16gene is found on chromosome 7 and produces leptin . Leptin 
acts as a feedback mechanism between the adipose tissue and 
the brain, acting as lipostat controlling fat stores by regulating 
16hunger and satiety . High leptin levels decrease food intake 
and increase energy expenditure. Mutation in either leptin or 
the leptin receptor has led to the development of  morbid early 
10onset diabetes in several families . Rarely, mutation in some 
other genes cause obesity in human's e.g mutation in tub gene 
which encodes a hypothalamic peptide of  unknown function, 
10causes late onset diabetes . A number of  complex human 
syndromes have also been associated with obesity such as 
Prader-Willi syndrome, Ahlstrom syndrome and Cohen 
syndrome.
 
Morbid obesity is very likely to have adverse effect on an 
2individual's health and is defined as BMI of  40kg/m  or 
2greater or 35kg/m  or greater in association with weight 
related co-morbidities which may include hypertension, type 
2 diabetes, coronary heart disease, dyslipidaemias, non-
alcoholic hepatic steatosis, obstructive sleep apnoea, 
osteoarthritis, reduced fertility and a greater susceptibility to 
17a range of  cancers .  Reduced life expectancy has been 
documented in obese patients irrespective of  ethnicity, age or 
18sex .
Treatment of Obesity:
The treatment options include diet and exercise programme, 
the use of  drugs and bariatric surgery.
Diet and exercise programme: it is the first step in the 
process of  losing weight. Nevertheless, in patients with 
morbid obesity, their value is limited. This is because their 
success rates are not consistent and their rates of  weight 
19regain are high .
Use of drugs: this is relatively common in the management 
of  obesity. Orlistat and sibutramine are the only drugs 
20licensed for this purpose . Orlistat is a saturated derivative of  
lipstatin, a potent natural inhibitor of  pancreatic lipase. It 
inhibits the conversion of  dietary fat into its absorbable form, 
thereby, preventing its absorption. Sibutramine creates a 
feeling of  satiety by centrally inhibiting serotonin and 
noradrenalin reuptake. In 2005, a meta-analysis of  drug 
treatment for obesity showed a mean weight loss of  2.9kg in 
one year for orlistat and 4.5kg for sibutramine and this was 
21insufficient to make any clinical difference . It was observed 
that when therapy is stopped, weight is almost invariably 
regained.
Bariatric surgery: this is the most effective treatment for 
morbid obesity producing long lasting weight loss and 
22improvement or remission of  co morbid conditions . In a 
randomized controlled trial comparing a group of  patients 
undergoing pharmacological treatment with a matched 
group of  patients undergoing obesity surgery, it was observed 
after 8 years of  follow-up that those who had bariatric surgery 
lost an average of  20kg while those treated medically did not 
23lose any weight compared with baseline .
In 2006, the National Institute for Health and Clinical 
Excellence (NICE) produced a set of  guidelines for selection 
24of  patients for obesity surgery . These include:
2 2a) The patient must have a BMI ≥40Kkg/m  or ≥35kg/m  
associated with serious obesity related co morbidity 
(type 2 diabetes, hypertension, obstructive sleep 
apnoea).
b) All non-surgical methods must have been tried and 
failed to produce clinically significant weight loss over 
a 6 month period.
c) The patient will receive intensive follow-up in a 
specialist service.
d) The patient is considered fit for anaesthesia.
e) The patient commits to the need for long-term follow-
up.
These guidelines also recognized that in patients with a 
2BMI>50kg/m , surgery can be offered without a trial 
18medication . The goals of  surgery are to achieve and 
maintain significant weight loss and to reverse or prevent 
many of  the obesity induced co morbidities. Bariatric surgery 
was first performed in the early 1960s and its use has 
increased dramatically, particularly in recent years. The 
surgical procedures are broadly divided into 2 groups: the 
25Restrictive and Malabsorptive  procedures .
RESTRICTIVE PROCEDURES
These procedures decrease the storage capacity of  the 
stomach. A small stomach pouch is associated with prompt 
filling by a small amount of  food, early satiety, decrease meal 
size and calorie intake, ultimately resulting in weight loss. 
Restrictive procedures are simpler to perform and they 
achieve good weight loss. The common restrictive procedures 
Figure 1: Roux-en-y Gastric Bypass
25Diagram is adapted from Benjamin et al
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are Roux-en-y Gastric Bypass, Gastric Banding, Vertical 
Banded Gastroplasty  and Sleeve Gastrectomy.  (Figure 1 — 
4)
Roux-en-y Gastric Bypass
It is a procedure in which a small upper stomach pouch is 
fashioned and divided from the remainder of  the stomach. 
Additionally, there is intestinal reconstruction which 
bypasses a portion of  the intestine thereby, creating some 
degree of  malabsorption and may result in dumping 
syndrome. This syndrome occurs following ingestion of  high 
carbohydrate meal and may result in diaphoresis, nausea, 
26palpitations, diarrhoea, abdominal pain or light headedness . 
Recently, laparoscopic techniques have been applied to 
accomplish the same procedure in an effort to reduce post 
27operative morbidities and improve the quality of  life . 
Bypassing the fundus of  the stomach which is the major 
production site of  ghrelin results in significant decrease in its 
28serum level and in turn the patient's apetite .
Early complication rate of  10% and mortality rate of  1% have 
29been reported . Complications may include bleeding, 
incisional or internal hernias, anastomotic leaks, strictures, 
thromboembolic events, marginal ulcerations, gall stone 
formation, surgical site infection, vitamin and protein 
malnutrition. These complications become reduced as the 
30learning curve increases following laparoscopic surgeries . 
Lifelong follow-up of  these patients is required in order to 
avoid vitamin and mineral deficiencies.
Some studies have shown that this procedure improves or 
resolves glucose intolerance and type 2 diabetes almost 
immediately in the majority of  patients even before weight 
31-32loss is observed . Other co morbid conditions such as 
performed at the bed side by a needle accessing of  the 
subcutaneous port which is sutured to the abdominal wall 
fascia.
The laparoscopic approach is standard with a very low 
34conversion rate to the open approach(0.3-1%) . It has the 
lowest complication rate of  0-0.7% among all the bariatric 
35procedures .  In 2.8% of  patients, erosion of  the band into the 
35gastric wall may occur  while in 2-14.2% of  patients, band 
prolapse or slipping of  the band from its intended site may 
36occur . Revision of  the band will be required in 1-13% of  
36patients .  Weight loss has been found to be 34.5-58% in 12 
Figure 2: Gastric Banding
25Diagram is adapted from Benjamin et al
hypertension(52-91.5%), sleep apnoea (74-97.8%) and 
hypercholesterolemia(63-97%), also have been noted to 
33resolve .
Gastric Banding
This is the least invasive among the frequently performed 
procedures. It consists of  a silicon elastomer with an 
adjustable inner balloon that effectively allows for control of  
the stomal aperture. The band encircles the proximal stomach 
to create a very small(15-20mls) pouch that effectively 
restricts the amount of  food ingested. Adjustments are later 
Figure 3: Vertical Banded Gastroplasty
25Diagram is adapted from Benjamin et al
37months and 36-87% in 24 months . There is also 
improvement in co morbidities like asthma, triglyceridaemia, 
38hypertension and type 2 diabetes .
Vertical Banded Gastroplasty
In this procedure, the stomach is portioned with a stapling 
device to create a very small proximal pouch. The stoma is 
then reinforced between the pouch and the gastric remnant 
with a mesh band thereby, limiting the passage of  food into 
39the body of  the stomoach . Filling of  the upper stomach 
pouch results in satiety, and decreased solid food 
consumption leads to weight loss.
Complications following this procedure include staple-line 
40dehiscence and stomal stenosis .  The inferior results of  this 
Figure 4: Sleeve Gastrectomy
25Diagram is adapted from Benjamin et al
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procedure when compared to other restrictive procedures in 
terms of  weight loss and resolution of  co morbidities has led 
41to its disfavour among most surgeons .
Sleeve Gastrectomy
This is a relatively new procedure originally published by 
42Marceau et al . This operation can be performed by either 
open or laparoscopic method. It is a restrictive surgery in 
which about 85% of  the stomach is removed leaving a 
cylindrical or sleeve-shaped stomach with a capacity ranging 
from 60-150cc. The stomach is reduced to about 15% of  its 
original size by surgical removal of  a large portion of  the 
stomach along the greater curvature. The open edges are then 
attached together with the help of  stapler to form a sleeve or 
tube with a banana shape. It permanently reduces the size of  
the stomach. Following this procedure, there is considerable 
reduction in the quantity of  food eaten and there is virtual 
elimination of  the hormone (Ghrelin) which stimulate 
43hunger .
Complication rate is small, about 0.5-1% and may include 
leakage along the staple line and post operative 
43haemorrhage .
MALABSORPTIVE  PROCEDURES
These procedures induce decrease small intestinal absorption 
of  nutrients calories by bypassing intestinal loops. This may 
lead to short bowel syndrome which results in negative 
energy balance and weight loss. Excessive protein calorie 
malnutrition and macro and micro nutrient deficiency often 
accompany the weight loss caused by malabsorption. These 
metabolic side effects have led to the limitation of  the wide 
stones, polyathralgia, cirrhosis, liver failure, metabolic 
derangements (metabolic bone disease, vitamin B12 and D 
45deficiency) that required surgical revision or reversal .
Biliopancreatic Diversion and Duodenal Switch
These procedures were developed to avoid the complications 
of  blind loop syndrome. The biliopancreatic diversion 
involves a distal (80%) gastrectomy and a roux-en-y 
reconstruction consisting of  a 200cm alimentary (food limb, 
46a long biliopancreatic limb and a 50cm common limb . The 
duodenal switch is a similar procedure but also includes a 
sleeve gastrectomy and duodenoileostomy to avoid 
complications of  marginal ulcer often seen in biliopancreatic 
47diversion . In spite of  the improvement in co morbid 
conditions and good long term weight loss following these 
procedures, long term complications of  protein calorie 
malnutrition, vitamin deficiencies, metabolic bone disease 
48and hepatic dysfunction are still major limitations .
CONCLUSION
The management of  obesity is complex, requiring a 
multidisciplinary approach involving the physicians, 
psychiatrists, dieticians, counsellors and surgeons. Research 
shows that morbid obesity is a disease that remains generally 
unresponsive to diet and drug therapy.
Surgery is the most effective treatment for morbid obesity 
producing long lasting weight loss and improvement or 
remission of  co morbid conditions.  Specific criteria must be 
met and the patient motivated and fully informed. The type of  
surgery offered depends on the patient, associated co 
morbidities and the experience of  the surgeon. Restrictive 
procedures are more commonly performed because they are 
simpler to perform and achieve good weight loss while 
avoiding the metabolic complications associated with 
malabsorptive procedures. However, life long support and 
behavioural modification are necessary for long term success.
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